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Posterior Acoustic Enhancement in
Hepatocellular Carcinoma
epatocellular carcinoma is a common and frequently fatal
cancer relentlessly increasing in incidence. It is at least the
third leading cause of cancer death in the world and the
ninth leading cause in the United States1; these rates are likely un-
derestimates because the most recent figures from the US Centers
for Disease Control and Prevention required histologic diagnosis,
whereas the clinical trend is toward acceptance of characteristic im-
aging as the standard for diagnosis.2,3 The incidence of hepatocel-
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ORIGINAL RESEARCH
Objectives—The purpose of this study was to assess sonographic appearances of hepa-
tocellular carcinoma with particular attention to posterior acoustic effects.
Methods—We performed an Institutional Review Board–approved retrospective re-
view of patients with hepatocellular carcinoma who had undergone sonographically
guided procedures in our department between 2001 and 2010. A total of 247 masses
thought to represent hepatocellular carcinoma were identified; 27 were excluded be-
cause of prior angioembolization (altering the sonographic appearance), alternate his-
tologic diagnoses, and incomplete patient information or imaging. Ultimately, 220
masses in 185 patients (138 men and 47 women; average age, 59.1 years) constituted
the study population. Preprocedure sonograms were reviewed in consensus by 3 ab-
dominal radiologists; the liver echo texture, lesion echogenicity, and posterior acoustic
effect were rated and correlated with patient data.
Results—The average mass size was 3.1 cm (range, 0.7–17 cm). In total, 84.1% of the
masses (n = 185) arose in abnormally echogenic/attenuating livers; 54.1% of the masses
(n = 119) were predominantly hypoechoic, 23.2% (n = 51) isoechoic, and 22.7% (n =
50) hyperechoic. Target-type morphologic characteristics were noted in 41 masses.
Many masses (52.7% [n = 116]) had no specific posterior acoustic effect, but nearly
half (46.4%) had either mild (n = 64) or marked (n = 38) posterior acoustic enhance-
ment. The remaining masses (0.9% [n = 2]) had posterior shadowing. Posterior acoustic
enhancement was most common among hyperechoic masses (62% with posterior
acoustic enhancement), target-type masses (63%), and masses larger than 5 cm
(81.5%). 
Conclusions—Posterior acoustic enhancement is present to some degree in almost half
of hepatocellular carcinomas, which may relate to the tissue characteristics of the tumor
or the cirrhotic liver itself. Attention to this finding, including scanning without spatial
compounding, is recommended during sonographic screening for hepatocellular car-
cinoma in the growing population of patients with liver disease.
Key Words—cirrhosis; hepatocellular carcinoma; hepatocellular carcinoma screening 
Article includes CME test
304jumvonline.qxp:Layout 1  3/18/11  12:01 PM  Page 495
lular carcinoma will almost certainly continue to increase
in the coming decades,1,4 and the importance of imaging
for diagnosis and management remains paramount.
Screening protocols for cirrhotic patients at high risk
for hepatocellular carcinoma have varied in their particu-
lars but generally include some combination of medical
surveillance, serum biomarkers including α-fetoprotein,
and sonography.5,6 The sensitivity of sonography for de-
tection of small lesions is limited,7,8 particularly in patients
with advanced steatosis or cirrhosis causing increased
background parenchymal echogenicity. The sonographic
appearance of hepatocellular carcinoma varies with the de-
gree of cellular differentiation and the presence of internal
hemorrhage or necrosis, among other factors.9–11
Given the large patient population undergoing screen-
ing and the potential importance of early detection for
these patients, optimization of technique is essential and
requires both modern high-resolution sonographic
equipment and awareness (by both sonographers and 
radiologists) of any characteristic imaging features that may
improve diagnostic performance in these difficult examina-
tions. Having incidentally noted the presence of posterior
acoustic enhancement associated with known hepatocellu-
lar carcinoma during a number of sonographically guided
interventional procedures, we reviewed our hepatocellu-
lar carcinoma database to determine the frequency of this
potentially useful finding.
Materials and Methods
Institutional Review Board approval was obtained for a
Health Insurance Portability and Accountability Act–
compliant retrospective review of sonograms obtained in
conjunction with biopsy or radio frequency ablation pro-
cedures performed from September 2001 through March
2010. The patient list was assembled from the cross-
 sectional interventional radiology database using the
search term “hepatocellular carcinoma.” Images (between
1 and 5) were saved on the radiology archive for each mass,
sometimes including cine clips, obtained on a variety of ul-
trasound machines. Imaging techniques, including the ma-
chines and transducers used, varied over the study period,
but 3- to 7-MHz transducers are typically used for liver im-
aging at our institution. Three subspecialist abdominal radi-
ologists (with 4, 5, and 12 years of postresidency experience,
respectively) reviewed these images in a consensus panel
and tabulated imaging characteristics. Patient records were
reviewed to confirm the pathologic diagnosis and establish
the presence and type of underlying liver disease, results of
other imaging studies, and basic demographics.
A total of 247 masses believed to represent hepato-
cellular carcinoma in 205 patients were initially identified,
and imaging was reviewed. Twenty-seven masses in 22 pa-
tients were excluded: 17 masses in 12 patients were in fact
metastases from other primary cancers; 5 masses had un-
dergone prior transarterial chemoembolization, altering
imaging characteristics; 2 had no images saved in the radi-
ology archive; 2 had no pathologic or clinical information
on the record review; and 1 mass was not visible on the im-
aging review. Two of the above 22 patients had 1 mass ex-
cluded and 1 mass included and therefore remained under
consideration.
A total of 185 patients thus constituted the study pop-
ulation, including 138 men and 47 women. The average age
was 59.1 years (range, 23–89 years). Of the 185 patients,
21 had no known liver disease before or after the diagnosis
of hepatocellular carcinoma. The remaining 164 patients
had diagnoses of (in decreasing order of frequency): hepa-
titis C, alcoholic cirrhosis, hepatitis B, cryptogenic cirrhosis,
hemochromatosis, primary biliary cirrhosis, α-1 antitrypsin
deficiency, autoimmune hepatitis, nonalcoholic steatohep-
atitis, and Budd-Chiari syndrome.
Ultimately, 220 masses remained under considera-
tion. The diagnosis of hepatocellular carcinoma in the
index mass was established by biopsy, resection, or pathol-
ogist review of the explanted liver for 149 masses (68%).
The index mass size and anatomic site were carefully cor-
related with biopsy images, surgical reports, and explant
review reports to confirm the lesion identity. An additional
30 masses (14%) had classic imaging findings in the con-
text of a prior tissue diagnosis of hepatocellular carcinoma
in another mass in the same patient.
Finally, the diagnosis of hepatocellular carcinoma was
established by imaging alone for 41 masses (18%). This cat-
egory required an arterially enhancing mass in a cirrhotic
liver, as shown by multiphasic computed tomography or
magnetic resonance imaging, with relative de-enhance-
ment on delayed imaging2,3 to be considered presumptive
hepatocellular carcinoma by the liver tumor board and
physicians performing interventions. All of the patients in
this group had documented chronic liver disease from a
variety of etiologies. Twenty-nine of these masses were as-
sociated with elevated serum α-fetoprotein levels; 10 were
associated with normal α-fetoprotein levels; and labora-
tory data were not available for 2 masses. 
Results
Readers subjectively rated the echo texture of the back-
ground liver parenchyma. The surrounding liver was con-
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sidered normal for only 35 masses (15.9%), whereas most
were somewhat (61.4% [n = 135]) or markedly (22.7% 
[n = 50]) echogenic or attenuating. The average lesion size
was 3.1 cm (range, 0.7–17 cm); 5 patients had diffuse (non-
measurable) disease. Most masses were hypoechoic com-
pared with background parenchyma (54.1% [n = 119]),
with smaller numbers of isoechoic (23.2% [n = 51]) and
hyperechoic (22.7% [n = 50]) masses. Note was also made
of the presence of target-type morphologic characteristics (a
hypoechoic rim surrounding a mass of variable echogenic-
ity), which were present in 41 masses (Figure 1).
Readers subjectively rated the dominant posterior
acoustic effect of the masses in the following 4 categories:
(1) definite or marked posterior acoustic enhancement
(Figure 2); (2) some or mild posterior acoustic enhance-
ment (Figure 3); (3) no specific effect; and (4) shadowing.
Results are shown in Table 1.
Discussion
Acoustic enhancement arises posterior to any lesion that
attenuates sound less than the surrounding tissue; the in-
tensity of the transmitted ultrasound beam is relatively
preserved distal to the lesion.12 Posterior acoustic en-
hancement is most commonly discussed in the context of
cystic lesions, which attenuate sound less than any soft tis-
sue structure, but a lesion need not be fluid filled to show
enhancement because the difference in transmission is rel-
ative. Therefore, we hypothesized that any lesion with a
simple internal architecture (or a homogeneous cell popu-
lation, such as hepatocellular carcinoma) might show pos-
terior acoustic enhancement in a cirrhotic liver. Indeed, we
found that posterior acoustic enhancement was present in
nearly half of the hepatocellular carcinomas we assessed, al-
though we did not observe any specific relationship with
the background parenchymal echogenicity.
Choi and colleagues11 observed a similar frequency of
posterior acoustic enhancement in a small population of
hepatocellular carcinomas smaller than 5 cm. This obser-
vation has not been widely incorporated into clinical prac-
tice, perhaps because its specificity remains unknown. For
example, the typical sonographic profile of hemangioma
(hyperechoic with posterior acoustic enhancement)
J Ultrasound Med 2011; 30:495–499 497
Maturen et al—Posterior Acoustic Enhancement in Hepatocellular Carcinoma
Figure 1. Sonogram from a 55-year-old man with hepatitis C and hepa-
tocellular carcinoma. An isoechoic mass (black arrows) with a hypo -
echoic target-like rim shows mild posterior acoustic enhancement
(white arrows).
Figure 2. Sonogram from a 52-year-old man with cryptogenic cirrhosis
and hepatocellular carcinoma. A small mildly hypoechoic mass
(calipers) shows marked posterior acoustic enhancement (arrows).
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would overlap with 31 hepatocellular carcinomas in our
study. The target morphologic characteristics we observed
in 41 hepatocellular carcinomas are frequently seen in
metastatic disease,13 and we have anecdotally observed
several metastases with posterior acoustic enhancement,
although this observation has not been specifically re-
ported, to our knowledge. However, metastasis and he-
mangioma are both less common in cirrhotic livers than
normal livers,14–16 and a high index of suspicion for hepa-
tocellular carcinoma would likely prevail in such patients.
We observed the most acoustic enhancement in as-
sociation with hyperechoic, target-type, and large lesions.
A potential explanation emerges from the tendency of
hepatocellular carcinoma to change in sonographic ap-
pearance over time. A commonly observed pattern is the
small hypoechoic hepatocellular carcinoma gradually be-
coming hyperechoic, attributed to the development of cen-
tral necrosis and fibrosis.9,17 This observation is in
accordance with the histologic identification of a viable
“proliferative” cell population at the margin of centrally
necrotic and fibrotic tumors, accounting for the hypoe-
choic rim in many target lesions.18 In other words, a well-
differentiated and centrally well-perfused hepatocellular
carcinoma is likely to be hypoechoic or isoechoic through-
out, whereas a more advanced tumor may become either
diffusely hyperechoic or targetlike and larger. The central
necrotic component may be more liquefactive than cellu-
lar, also decreasing sound attenuation. Thus, posterior
acoustic enhancement is more likely to be associated with
more advanced cancers, which unfortunately limits the ap-
plication of this finding in the context of screening for early
hepatocellular carcinoma.
Ultrasound scanning techniques are notoriously vari-
able and of clear importance. Spatial compounding is com-
monly used in sonography to improve the “sharpness” of
images by reducing speckle, but its use of multiple non-
parallel angles of insonation reduces posterior acoustic
effects, including both shadowing and enhancement.19
We suggest therefore that screening examinations for he-
patocellular carcinoma should include some evaluation
without compounding because posterior acoustic enhance-
ment may facilitate detection of a subtle or an iso echoic
nodule. In fact, this study may have underestimated the
frequency of demonstrable posterior acoustic effects in 
hepatocellular carcinoma because spatial compounding
was routinely left on for interventional procedures.
This study had several limitations. The sonograms re-
viewed were not diagnostically optimized, intended only
to identify masses before intervention. A subset of the cases
were not pathologically proven, although all of these arose
in the setting of chronic liver disease, most with elevated
serum α-fetoprotein levels, and all had imaging confirma-
tion in accordance with the current standard of care.2 Our
pathology reports do not routinely indicate the degree of
differentiation or necrosis of hepatocellular carcinoma, so
we are unable to provide detailed histologic correlations
for the imaging findings. Finally, we are unable to assess
the sensitivity or specificity of posterior acoustic enhance-
ment for lesion detection or characterization, respectively,
because the population was composed entirely of known
hepatocellular carcinomas. Complete evaluation of this im-
aging sign would require the inclusion of control patients
and a prospective approach with a standardized sono-
graphic technique.
In summary, posterior acoustic enhancement is ob-
served in nearly half of hepatocellular carcinomas and may
be more frequently associated with advanced cancers. The
hepatocellular carcinomas in our study were pleomorphic,
with some mimicking benign hemangiomas: echogenic
with posterior acoustic enhancement. The sensitivity and
specificity of posterior acoustic enhancement for hepato-
cellular carcinoma remain unknown, but given the in-
creasing hepatocellular carcinoma screening population
and the importance of containing medical costs and radi-
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Figure 3. Sonogram from a 60-year-old man with hepatitis C, alcoholic
cirrhosis, and hepatocellular carcinoma. A small hypoechoic mass
(calipers) shows mild posterior acoustic enhancement (arrows).
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ation doses, we must make the best use of the tools we
have. Attention to posterior acoustic effects by sonogra-
phers and radiologists, including evaluation without spa-
tial compounding, may contribute to the success of
sonographic screening for hepatocellular carcinoma in the
cirrhotic liver.
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Table 1. Posterior Acoustic Enhancement in Hepatocellular Carcinomas
Posterior Acoustic No Posterior Acoustic
Category Enhancement (Mild or Marked), % (n) Enhancement, % (n)
Cumulative
All masses (n = 220) 46.4 (102) 53.6 (118)a
Subset
Target-type masses (n = 41) 63 (26) 37 (15)
Hypoechoic masses (n = 119) 46.2 (55) 53.8 (64)
Isoechoic masses (n = 51) 31.4 (16) 68.6 (35)
Hyperechoic masses (n = 50) 62 (31) 38 (19)
Small masses (<2.5 cm; n = 111) 30.6 (34) 69.4 (77)
Medium masses (2.6–5.0 cm; n = 77) 58.4 (45) 41.6 (32)
Large masses (>5 cm; n = 27) 81.5 (22) 18.5 (5)
Highly echogenic background liver (n = 50) 42 (21) 58 (29)
Somewhat echogenic background liver (n = 135) 47.5 (64) 52.5 (71)
Sonographically normal liver (n = 35) 48.5 (17) 51.5 (18)
aTwo masses had posterior acoustic shadowing but were included in the No Posterior Acoustic Enhancement group.
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